Total Valuation
Santen Pharmaceutical Co has a market cap or net worth of €3.36B. The enterprise value is €3.36K.
Market Cap€3.36B
Enterprise Value€3.36K
Share Statistics
Santen Pharmaceutical Co has 322,290,160 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding322,290,160
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Santen Pharmaceutical Co’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 10.87%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)10.87%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee75.61M
Profits Per Employee9.14M
Employee Count3,968
Asset Turnover0.73
Inventory Turnover2.50
Valuation Ratios
The current PE Ratio of Santen Pharmaceutical Co is 16.5. Santen Pharmaceutical Co’s PEG ratio is 0.87.
PE Ratio16.5
PS Ratio1.87
PB Ratio1.94
Price to Fair Value1.73
Price to FCF14.88
Price to Operating Cash Flow―
PEG Ratio0.87
Income Statement
In the last 12 months, Santen Pharmaceutical Co had revenue of 300.00B and earned 36.26B in profits. Earnings per share was 103.98.
Revenue300.00B
Gross Profit171.03B
Operating Income46.88B
Pretax Income47.48B
Net Income36.26B
EBITDA59.01B
Earnings Per Share (EPS)103.98
Cash Flow
In the last 12 months, operating cash flow was 60.93B and capital expenditures -6.66B, giving a free cash flow of 54.27B billion.
Operating Cash Flow60.93B
Free Cash Flow54.27B
Free Cash Flow per Share168.38
Dividends & Yields
Santen Pharmaceutical Co pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.08
52-Week Price Change7.02%
50-Day Moving Average10.84
200-Day Moving Average9.56
Relative Strength Index (RSI)25.79
Average Volume (3m)10.00
Important Dates
Santen Pharmaceutical Co upcoming earnings date is Aug 6, 2026, TBA (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Santen Pharmaceutical Co as a current ratio of 2.58, with Debt / Equity ratio of ―
Current Ratio2.58
Quick Ratio1.99
Debt to Market Cap<0.01
Net Debt to EBITDA-1.00
Interest Coverage Ratio17.26
Taxes
In the past 12 months, Santen Pharmaceutical Co has paid 11.63B in taxes.
Income Tax11.63B
Effective Tax Rate0.24
Enterprise Valuation
Santen Pharmaceutical Co EV to EBITDA ratio is 7.39, with an EV/FCF ratio of 8.04.
EV to Sales1.45
EV to EBITDA7.39
EV to Free Cash Flow8.04
EV to Operating Cash Flow7.16
Balance Sheet
Santen Pharmaceutical Co has €93.99B in cash and marketable securities with €34.90B in debt, giving a net cash position of €59.77B billion.
Cash & Marketable Securities€93.99B
Total Debt€34.90B
Net Cash€59.77B
Net Cash Per Share€185.44
Tangible Book Value Per Share€601.58
Margins
Gross margin is ―, with operating margin of 15.63%, and net profit margin of 12.09%.
Gross Margin―
Operating Margin15.63%
Pretax Margin15.83%
Net Profit Margin12.09%
EBITDA Margin19.67%
EBIT Margin16.73%
Analyst Forecast
The average price target for Santen Pharmaceutical Co is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-9.07%
EPS Growth Forecast1.94%